Enliven net loss widens 28.2% to $32.5 million in Q2 FY26 - ELVN News | RalliesEnliven net loss widens 28.2% to $32.5 million in Q2 FY26
E
ELVN• Q2 financial results
- Enliven Therapeutics posted a Q2 net loss of $32.49 million, worsening from $25.34 million a year earlier.
- R&D expenses climbed to $29 million from $21.5 million year-on-year; G&A costs rose to $8.21 million from $7.09 million.
Cash position and runway
- Cash, cash equivalents and marketable securities totaled $895.2 million at June 30, with runway expected into 2030.
ELVN-001 development update
- Updated Phase 1 ELVN-001 data showed 61% overall MMR, 48% MMR by 24 weeks in the 80 mg QD Phase 1b cohort.
- FDA alignment set 80 mg QD for the Phase 3 ENABLE-2 design, with trial initiation expected in the second half of 2026.
